- Home
- KURA vs CAC Comparison
KURA vs CAC Comparison
Compare KURA & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | CAC |
|---|---|---|
| Founded | 2014 | 1875 |
| Country | United States | United States |
| Employees | 260 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 857.1M |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KURA | CAC |
|---|---|---|
| Price | $9.23 | $47.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $25.56 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.2M | 76.4K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | N/A | ★ 6.08 |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $67,482,000.00 | $41,739,000.00 |
| Revenue This Year | $28.28 | $19.15 |
| Revenue Next Year | $106.37 | $6.05 |
| P/E Ratio | ★ N/A | $36.78 |
| Revenue Growth | ★ 25.24 | 16.96 |
| 52 Week Low | $5.45 | $35.00 |
| 52 Week High | $12.49 | $53.71 |
Technical Indicators
Market Signals| Indicator | KURA | CAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 41.99 |
| Support Level | $8.95 | $47.25 |
| Resistance Level | $9.82 | $51.57 |
| Average True Range (ATR) | 0.43 | 1.42 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 50.34 | 6.40 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.